Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9497821 | 0.83 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL2392882 | 0.81 | ALDH1A1 (0.48) | CA2CA7CA14POLBHDAC6 | |
| SCHEMBL28307781 | 0.79 | MEN1 (0.36) | ALDH1A1 | |
| SCHEMBL12335918 | 0.79 | RIPK1 (0.46) | POLBL3MBTL1RAB9A | |
| SCHEMBL9497704 | 0.79 | CFTR (0.31) | — | |
| SCHEMBL24574899 | 0.79 | SMN1; SMN2 (0.45) | CA1CA2CA7CA14POLB | |
| SCHEMBL26629354 | 0.79 | PREP (0.40) | CA1CA2CA7CA14POLB | |
| SCHEMBL8962237 | 0.79 | POLB (0.38) | CA1CA2CA7CA14POLB | |
| Hydrochloric Acid SCHEMBL28308666 | 0.78 | MEN1 (0.35) | ALDH1A1 | |
| SCHEMBL2040611 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014147640-A2 | PROCESS FOR THE PREPARATION OF ANAGLIPTIN | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-09-25 | — | — | WO | disclosed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | CA1 4570/4885CA2 2090/4885CA7 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.